These apps and software programs could provide access to lifesaving screening – if researchers can find a way to remove the baked-in bias.

Recent reporting and rumors may have one believe that cigarettes are cool and popular again among young Americans. The data don’t bear this out—fewer young people smoke than ever—but a reminder of smoking’s dangers nevertheless feels warranted.
The post A Reminder: Smoking Still Causes Cancer appeared first on American Association for Cancer Research (AACR).

Cancer Research Catalyst has launched a new monthly series, “Unboxing Cancer News,” that highlights exciting cancer research discoveries. Read the first installment and learn about transmissible cancer in catfish, federal- vs. industry-sponsored trials, symptoms that may predict early-onset colorectal cancer, and engineered yeast that produce ingredients to make chemotherapy drugs.
The post Unboxing Cancer News, August 2026: Fishy Cancer, Federal- vs. Industry-funded Trials, and More   appeared first on American Association for Cancer Research (AACR).

Around 97% of patients with advanced pancreatic cancer die within five years. Researchers have figured out a way to target the mechanism that makes these tumors so deadly.

Today, the U.S. Food and Drug Administration approved daraxonrasib (Rasonque), a groundbreaking new drug for pancreatic cancer that targets the RAS family of proteins. Catch up on the amazing progress scientists have made in targeting RAS by reading the AACR blog’s extensive coverage of the field, from the discovery of RAS as an oncogene to the development of drugs targeting this once-elusive protein and the new advances on the horizon.
The post Breaking News: Daraxonrasib Approved for Pancreatic Cancer appeared first on American Association for Cancer Research (AACR).

The August 2026 Editors’ Picks from AACR journals cover the impact of weight loss and omega-3 supplementation on breast cancer risk, early-onset cancer prediction, and more.
The post Editors’ Picks, August 2026: Weight Loss and Breast Cancer Biomarkers, Predicting Early-onset Cancer Cases, and More appeared first on American Association for Cancer Research (AACR).

Ovarian cancer is often diagnosed at an advanced stage, but research is reshaping how scientists understand and treat the disease. From discoveries about its origins to new FDA-approved therapies, learn how scientific advances are creating new possibilities for patients, including the first immunotherapy-based regimen for this cancer type and a first-of-its-kind selective glucocorticoid receptor antagonist.
The post How New Science is Reshaping Ovarian Cancer Treatment and Care appeared first on American Association for Cancer Research (AACR).

A variety of national and local news outlets have highlighted AACR initiatives and experts in recent weeks. Learn about the news stories covering the findings from the AACR Cancer Disparities Progress Report 2026 and AACR’s statement about the White House Office of Management and Budget’s proposal to change how federal grants are awarded and managed.
The post AACR in the News: Cancer Disparities Progress Report and OMB Statement appeared first on American Association for Cancer Research (AACR).

We highlight some of the many innovations showcased at the inaugural AACR Drug Discovery and Development (AACR D3) conference, including investigational KRAS degraders, approaches to drug p53 and MYC, and new AI tools for drug discovery.
The post AACR D3 Offered a Peek Into the Cancer Drug Pipeline, Innovative AI Tools, and More appeared first on American Association for Cancer Research (AACR).

Menopausal hormone therapy no longer has the highest-level warning label about the risk of breast cancer, opening a gray area on who would benefit most from treatment.